TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02775721

Intervention type: OTHER
Group type: OTHER
Intervention: Nutritional Therapy Education and Evaluation
Description: Nutritional therapy will be conducted per standard of care, the protocol does not dictate the frequency or treatment plan of care. Nutritional therapy and evaluation is assessed per the attending dietitian. The study team will collect all data related to nutritional therapy education and evaluation at each study visit per protocol. All collected data will be utilized in final protocol analysis.

Intervention type: OTHER
Group type: OTHER
Intervention: Nutritional Therapy Education and Evaluation
Description: Nutritional therapy will be conducted per standard of care, the protocol does not dictate the frequency or treatment plan of care. Nutritional therapy and evaluation is assessed per the attending dietitian. The study team will collect all data related to nutritional therapy education and evaluation at each study visit per protocol. All collected data will be utilized in final protocol analysis.

Intervention type: OTHER
Group type: OTHER
Intervention: Nutritional Therapy Education and Evaluation
Description: Nutritional therapy will be conducted per standard of care, the protocol does not dictate the frequency or treatment plan of care. Nutritional therapy and evaluation is assessed per the attending dietitian. The study team will collect all data related to nutritional therapy education and evaluation at each study visit per protocol. All collected data will be utilized in final protocol analysis.

Intervention type: OTHER
Group type: OTHER
Intervention: Quality of Life Questionnaire C30 version 3
Description: 30-item instrument that measures the Health Related Quality of Life (HRQoL) in a wide range of cancer patient populations.

Intervention type: OTHER
Group type: OTHER
Intervention: Quality of Life Questionnaire C30 version 3
Description: 30-item instrument that measures the Health Related Quality of Life (HRQoL) in a wide range of cancer patient populations.

Intervention type: OTHER
Group type: OTHER
Intervention: Quality of Life Questionnaire C30 version 3
Description: 30-item instrument that measures the Health Related Quality of Life (HRQoL) in a wide range of cancer patient populations.

Intervention type: OTHER
Group type: OTHER
Intervention: Quality of Life Questionnaire EORTC QLO - H&N35
Description: 35-item instrument that measures the Health Related Quality of Life specific to Head and Neck cancer patient populations.

Intervention type: OTHER
Group type: OTHER
Intervention: Quality of Life Questionnaire EORTC QLO - H&N35
Description: 35-item instrument that measures the Health Related Quality of Life specific to Head and Neck cancer patient populations.

Intervention type: OTHER
Group type: OTHER
Intervention: Quality of Life Questionnaire EORTC QLO - H&N35
Description: 35-item instrument that measures the Health Related Quality of Life specific to Head and Neck cancer patient populations.
Study: NCT02240160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: Oromucosal spray containing THC (27 mg/mL) and CBD (25 mg/mL) in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Each 100 μL spray delivers 2.7 mg THC and 2.5 mg CBD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: Oromucosal spray containing THC (27 mg/mL) and CBD (25 mg/mL) in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Each 100 μL spray delivers 2.7 mg THC and 2.5 mg CBD.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: Oromucosal spray containing THC (27 mg/mL) and CBD (25 mg/mL) in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Each 100 μL spray delivers 2.7 mg THC and 2.5 mg CBD.
Study: NCT04054388

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LINE re-education
Study: NCT02698475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 0.75 mg/kg
Description: Participants weighing less than (\<) 60 kilograms will receive ustekinumab 0.75 milligram per kilogram (mg/kg) at Weeks 0 and 4 followed by every 12 weeks dosing with the last dose at Week 40. Eligible participants for LTE period will continue to receive ustekinumab 0.75 mg/kg up to Week 248.
Study: NCT00754624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Technosphere® Insulin Inhalation Powder and MedTone™ Inhaler
Description: Inhalation starting at 15, 30, or 60U doses and can be titrated up or down by 15U to a minimum of 15U or a maximum of 90U
Study: NCT03132376

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Water Preload Drink
Description: Participants were given 275 ml (0 kcal) water to consume in the morning following an overnight fast. This served as the control drink.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey Protein Isolate Drink
Description: Participants were given an isovolumetric (to the water), 160 kcal drink with 30 g whey protein to consume in the morning following an overnight fast.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Micellar Casein Protein Drink
Description: Participants were given an isovolumetric (to the water), 160 kcal drink with 30 g micellar casein to consume in the morning following an overnight fast.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Egg White Isolate Protein Drink
Description: Participants were given an isovolumetric (to the water), 160 kcal drink with 30 g egg white isolate protein to consume in the morning following an overnight fast.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Egg White Concentrate Protein Drink
Description: Participants were given an isovolumetric (to the water), 160 kcal drink with 30 g egg white concentrate protein to consume in the morning following an overnight fast.
Study: NCT03096210

Intervention type: OTHER
Group type: OTHER
Intervention: Titanium-Prepared Platelet Rich Fibrin
Description: Blood samples were collected from the each participant's arm in the test group by 20 ml syringe and then was transferred into 10ml grade IV titanium tube without anticoagulant. After centrifugation of blood samples (2800 rpm, 12 minutes) at room temperature, the T-PRF clot was removed from the tubes with sterile tweezers. 6 blood tubes were collected for a sinus floor elevation/lifting operation and 6 T-PRFs were prepared for each participant.
Study: NCT02698475

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 45 mg
Description: Participants weighing greater than or equal to (\>=) 60 kg to less than or equal to (\<=) 100 kg will receive ustekinumab 45 mg at Weeks 0 and 4 followed by every 12 weeks dosing with the last dose at Week 40. Eligible participants for LTE period will continue to receive ustekinumab 45 mg up to Week 248.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ustekinumab 90 mg
Description: Participants weighing \>100 kg will receive ustekinumab 90 mg at Weeks 0 and 4 followed by every 12 weeks dosing with the last dose at Week 40. Eligible participants for LTE period will continue to receive ustekinumab 90 mg up to Week 248.
Study: NCT03096210

Intervention type: OTHER
Group type: OTHER
Intervention: Allograft (CTBA Allograft)
Description: After careful elevation of the schneiderian membrane without perforation, allograft was only used for augmentation of the sinus floor in the control group.
Study: NCT01564797

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Home Health Party
Description: An education-based lay health educator-led intervention designed to educate Hispanic participants with elevated HA1c levels about diabetes, treatment of diabetes, and diet and lifestyle changes.
Study: NCT00418314

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Empiric programming or one-time optimization using a non-IEGM method.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: QuickOpt
Description: Frequent optimization using QuickOpt to optimize AV/PV and VV delays.
Study: NCT01920568

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D supplement
Description: Subjects are strongly recommended to take daily supplements of at least 400 IU of vitamin D from the day of consent and until completion of the Week 73 follow-up visit.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D supplement
Description: Subjects are strongly recommended to take daily supplements of at least 400 IU of vitamin D from the day of consent and until completion of the Week 73 follow-up visit.
Study: NCT02687555

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification of Appraisals (CBM-App)

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Peripheral Vision Task (control condition)
Study: NCT02694068

Intervention type: OTHER
Intervention: Peritoneal Equilibrium Test
Description: These will be done as part of standard of care procedures. PETs will not be performed solely for research purposes.

Intervention type: OTHER
Intervention: Peritoneal Equilibrium Test
Description: These will be done as part of standard of care procedures. PETs will not be performed solely for research purposes.

Intervention type: OTHER
Intervention: Peritoneal Equilibrium Test
Description: These will be done as part of standard of care procedures. PETs will not be performed solely for research purposes.

Intervention type: OTHER
Intervention: Peritoneal Equilibrium Test
Description: These will be done as part of standard of care procedures. PETs will not be performed solely for research purposes.

Intervention type: OTHER
Intervention: 4 hour dwell of 2.5/4.25% dextrose solution
Description: If a PET is not performed annually as part of standard of care, subjects will undergo a 4 hour timed dwell with either 2.5 or 4.25% dextrose solution. This will be for the purposes of sample collection and/or measurement of ultrafiltration capacity.

Intervention type: OTHER
Intervention: 4 hour dwell of 2.5/4.25% dextrose solution
Description: If a PET is not performed annually as part of standard of care, subjects will undergo a 4 hour timed dwell with either 2.5 or 4.25% dextrose solution. This will be for the purposes of sample collection and/or measurement of ultrafiltration capacity.

Intervention type: OTHER
Intervention: 4 hour dwell of 2.5/4.25% dextrose solution
Description: If a PET is not performed annually as part of standard of care, subjects will undergo a 4 hour timed dwell with either 2.5 or 4.25% dextrose solution. This will be for the purposes of sample collection and/or measurement of ultrafiltration capacity.

Intervention type: OTHER
Intervention: 4 hour dwell of 2.5/4.25% dextrose solution
Description: If a PET is not performed annually as part of standard of care, subjects will undergo a 4 hour timed dwell with either 2.5 or 4.25% dextrose solution. This will be for the purposes of sample collection and/or measurement of ultrafiltration capacity.
Study: NCT02940145

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: The investigation was carried out over a period of 16 weeks, with 12 weeks dedicated to the RT program and 4 weeks allocated for measurements. Anthropometric, body composition, and blood samples measurements were performed at weeks 1-2, and 15-16. A supervised progressive RT was performed between weeks 3-14. The CG did not perform any type of physical exercise during this period.
Study: NCT02554669

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: postprandial and postabsorptive physical activity on treadmill

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: postprandial and postabsorptive physical activity on treadmill
Study: NCT00894569

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: paclitaxel/carboplatin
Description: 6 cycles paclitaxel 175 mg/m² and carboplatin AUC 5, repetition d22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel/carboplatin
Description: 6 cycles paclitaxel 175 mg/m² and carboplatin AUC 5, repetition d22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: cetuximab (400 mg/m² first dose, 250 mg/m² weekly) until disease progression
Study: NCT03029377

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Posture Study, Autonomic Function Tests, and a Stress Test
Description: Participants will undergo a Posture Study, Autonomic Function Tests, and a Stress Test. Participants' blood will be drawn to measure markers of sympathetic nervous system function at baseline, in three postural positions, after autonomic tests, and after a stress test.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Posture Study, Autonomic Function Tests, and a Stress Test
Description: Participants will undergo a Posture Study, Autonomic Function Tests, and a Stress Test. Participants' blood will be drawn to measure markers of sympathetic nervous system function at baseline, in three postural positions, after autonomic tests, and after a stress test.
Study: NCT00099853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: Vildagliptin 50 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin
Description: Vildagliptin 50 mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Description: pioglitazone 45 mg qd

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pioglitazone
Description: pioglitazone 45 mg qd

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: pioglitazone
Description: pioglitazone 45 mg qd

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Vildagliptin matching placebo
Study: NCT00507962

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 100 mg/m\^2 Intraarterial On Day 1 Every 4 Weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Liposomal Doxorubicin
Description: Starting dose 20 mg/m\^2 IV On Day 1 Every 4 Weeks
Study: NCT01356472

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: Imipenem/cilastatin
Description: the intervention group was designed for combined linezolid plus imipenem for treating MRSA VAP
Study: NCT01741324

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D 25 microg/d
Description: The vitamin D supplement will be provided as a milk drink taken daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D 25 microg/d
Description: The vitamin D supplement will be provided as a milk drink taken daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D 25 microg/d
Description: The vitamin D supplement will be provided as a milk drink taken daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D 25 microg/d
Description: The vitamin D supplement will be provided as a milk drink taken daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D 10 microg/d
Description: The vitamin D supplement will be provided as a milk drink taken daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D 10 microg/d
Description: The vitamin D supplement will be provided as a milk drink taken daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D 10 microg/d
Description: The vitamin D supplement will be provided as a milk drink taken daily.
Study: NCT03876184

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aesthetic archwires
Description: During bond-up, randomly allocated envelope will be opened and archwires will be ligated with elastomeric ligatures.After 4 weeks,the same archwires will be retied.Any fractured archwire will be recorded and discarded.The fractured wire will be replaced with conventional archwire and treatment continues.On the 2nd follow-up (at 8th week), the tested wires are collected, disinfected, dried and placed back in the allocated envelope.Upper and lower impressions will be taken.Questionnaires will be answered by participants.The trial ends and treatment continues as planned.Fractured archwire will be recorded and discarded.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aesthetic archwires
Description: During bond-up, randomly allocated envelope will be opened and archwires will be ligated with elastomeric ligatures.After 4 weeks,the same archwires will be retied.Any fractured archwire will be recorded and discarded.The fractured wire will be replaced with conventional archwire and treatment continues.On the 2nd follow-up (at 8th week), the tested wires are collected, disinfected, dried and placed back in the allocated envelope.Upper and lower impressions will be taken.Questionnaires will be answered by participants.The trial ends and treatment continues as planned.Fractured archwire will be recorded and discarded.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aesthetic archwires
Description: During bond-up, randomly allocated envelope will be opened and archwires will be ligated with elastomeric ligatures.After 4 weeks,the same archwires will be retied.Any fractured archwire will be recorded and discarded.The fractured wire will be replaced with conventional archwire and treatment continues.On the 2nd follow-up (at 8th week), the tested wires are collected, disinfected, dried and placed back in the allocated envelope.Upper and lower impressions will be taken.Questionnaires will be answered by participants.The trial ends and treatment continues as planned.Fractured archwire will be recorded and discarded.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control group
Description: During bond-up, randomly allocated envelope will be opened and archwires will be ligated with elastomeric ligatures.After 4 weeks,the same archwires will be retied.Any fractured archwire will be recorded and discarded.The fractured wire will be replaced with conventional archwire and treatment continues.On the 2nd follow-up (at 8th week), the tested wires are collected, disinfected, dried and placed back in the allocated envelope.Upper and lower impressions will be taken.This group will not answer the questionnaire.The trial ends and treatment continues as planned.Fractured archwire will be recorded and discarded.
Study: NCT01741324

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D 10 microg/d
Description: The vitamin D supplement will be provided as a milk drink taken daily.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: No extra vitamin D
Description: Milk drink with no extra vitamin D (placebo)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: No extra vitamin D
Description: Milk drink with no extra vitamin D (placebo)
Study: NCT01643252

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: riboflavin: 0.12% riboflavin ophthalmic solution with the KXL system
Description: Subjects will receive 0.12% riboflavin ophthalmic solution (VibeX) followed by irradiation with the KXL system at 30mW/cm\^2 for 4 minutes

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo: 0.0% riboflavin ophthalmic solution with the KXL system
Description: Subjects will receive 0.0% riboflavin ophthalmic solution (placebo) followed by irradiation with the KXL system at 30mW/cm\^2 for 4 minutes
Study: NCT00904098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Frovatriptan
Description: This study employed a prospective, non-randomized, open-label single-sequence design. The study was conducted in two phases:~1. A Usual Care phase (approximately 1 month in duration) included one menstrual period during which female patients treated all episodes of migraine headaches using their current treatment (referred to as the Baseline phase in the protocol)~2. An Acute Treatment phase (approximately 1 month in duration), following the Usual Care phase, included one menstrual period during which female patients used frovatriptan 2.5 mg to treat all episodes of migraine headache when their headache reached IHS Grade 1. If needed, a second dose of frovatriptan 2.5 mg was administered; however, this second dose could not be administered within 2 hours of the initial dose (i.e., there must have been at least 2 hours between doses of frovatriptan). The total daily dose of frovatriptan was not to exceed 3 tablets over a 24-hour period.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Current treatment used to treat all migraine headaches
Study: NCT03745443

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: increase and decrease positive end-expiratory pressure
Description: 20 minutes before the end of anesthesia and surgery PEEP was increased by 2 on every 5 breaths to 11. Ventilation with PEEP 11 was maintained for 2 minutes. Then, PEEP was reduced by 2 on every 5 breaths to 5 cmH2O
Study: NCT03836833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABC/3TC/LPV/r granules (30/15/40/10 mgs)
Description: This is a fixed dose combination. Each capsule contains Lopinavir (40mg), Ritonavir (10mg), Abacavir (30mg) and Lamivudine (15mg) in granules formulation.~Dosage according to patient's weight:~Between 3 and 5.9kg: 2 capsules twice a day Between 6 and 9.9kg: 3 capsules twice a day Between 10 and 13.9kg: 4 capsules twice a day Between 14 and 19.9kg: 5 capsules twice a day Between 20 and 24.9kg: 6 capsules twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABC/3TC/LPV/r granules (30/15/40/10 mgs)
Description: This is a fixed dose combination. Each capsule contains Lopinavir (40mg), Ritonavir (10mg), Abacavir (30mg) and Lamivudine (15mg) in granules formulation.~Dosage according to patient's weight:~Between 3 and 5.9kg: 2 capsules twice a day Between 6 and 9.9kg: 3 capsules twice a day Between 10 and 13.9kg: 4 capsules twice a day Between 14 and 19.9kg: 5 capsules twice a day Between 20 and 24.9kg: 6 capsules twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPV/r Pellets (40/10mgs) plus ABC/3TC (60/30mgs)
Description: Lopinavir/Ritonavir (40/10mg pellets) plus dual Abacavir/Lamivudine (60/30mg dispersible tablets)~Dosage according to patient's weight:~LPV/r Pellets:~Between 3 and 5.9kg: 2 capsules twice a day Between 6 and 9.9kg: 3 capsules twice a day Between 10 and 13.9kg: 4 capsules twice a day Between 14 and 19.9kg: 5 capsules twice a day Between 20 and 24.9kg: 6 capsules twice a day~ABC/3TC:~Between 3 and 5.9kg: 1 tablet twice a day Between 6 and 9.9kg: 1.5 tablets twice a day Between 10 and 13.9kg: 2 tablets twice a day Between 14 and 19.9kg: 2.5 tablets twice a day Between 20 and 24.9kg: 3 tablets twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LPV/r Pellets (40/10mgs) plus ABC/3TC (60/30mgs)
Description: Lopinavir/Ritonavir (40/10mg pellets) plus dual Abacavir/Lamivudine (60/30mg dispersible tablets)~Dosage according to patient's weight:~LPV/r Pellets:~Between 3 and 5.9kg: 2 capsules twice a day Between 6 and 9.9kg: 3 capsules twice a day Between 10 and 13.9kg: 4 capsules twice a day Between 14 and 19.9kg: 5 capsules twice a day Between 20 and 24.9kg: 6 capsules twice a day~ABC/3TC:~Between 3 and 5.9kg: 1 tablet twice a day Between 6 and 9.9kg: 1.5 tablets twice a day Between 10 and 13.9kg: 2 tablets twice a day Between 14 and 19.9kg: 2.5 tablets twice a day Between 20 and 24.9kg: 3 tablets twice a day
Study: NCT03897725

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Telehealth Coaching
Description: Telehealth coaching to promote adherence